The Asia Pacific prostate cancer nuclear medicine market is expected to grow from US$ 156.10 million in 2022 to US$ 295.37 million by 2028; it is estimated to grow at a CAGR of 11.2% from 2022 to 2028.
Nuclear medicine is mostly used to diagnose cardiovascular disease and cancer. Since the nuclear medicine industry is saturated, many companies and stakeholders are focusing on extending radiopharmaceutical uses in general. The demand and uptake of radiopharmaceuticals are projected to rise as their application areas grow, which would help businesses broaden their product lines and market share in neurological applications in the coming years. PET is a noninvasive nuclear imaging method for cancer diagnosis, staging, and treatment monitoring. PET imaging is done by injecting a positron-tagged radiopharmaceutical into a patient, usually intravenously. Precise imaging may aid physicians in providing better treatment in the era of individualized cancer treatments. The use of modern imaging is growing as it helps get accurate local staging and early metastatic cancer discovery, accurate oligometastatic disease identification, and optimal therapy response assessment. Next-generation imaging modalities, such as whole-body MRI and molecular imaging with combined PET and CT and PET and MRI combination employing innovative radiopharmaceuticals, provide new imaging options for patients with advanced prostate cancer.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC prostate cancer nuclear medicine market. The APAC prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
APAC Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
APAC Prostate cancer nuclear medicine Market Segmentation
The APAC prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the APAC prostate cancer nuclear medicine market is segmented into PET and SPECT. The PET dominated the APAC prostate cancer nuclear medicine market in 2022. Based on PET product, the APAC prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on end user, the APAC prostate cancer nuclear medicine market is segmented into hospitals, clinics, and others. The hospitals segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on country, the APAC prostate cancer nuclear medicine market is segmented into China, Japan, India, South Korea, Australia, and the Rest of APAC. The China segment dominated the APAC prostate cancer nuclear medicine market in 2022.
ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the APAC prostate cancer nuclear medicine market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 156.10 Million |
| Market Size by 2028 | US$ 295.37 Million |
| CAGR (2022 - 2028) | 11.2% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Prostate Cancer Nuclear Medicine Market is valued at US$ 156.10 Million in 2022, it is projected to reach US$ 295.37 Million by 2028.
As per our report Asia Pacific Prostate Cancer Nuclear Medicine Market, the market size is valued at US$ 156.10 Million in 2022, projecting it to reach US$ 295.37 Million by 2028. This translates to a CAGR of approximately 11.2% during the forecast period.
The Asia Pacific Prostate Cancer Nuclear Medicine Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Prostate Cancer Nuclear Medicine Market report:
The Asia Pacific Prostate Cancer Nuclear Medicine Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Prostate Cancer Nuclear Medicine Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Prostate Cancer Nuclear Medicine Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Prostate Cancer Nuclear Medicine Market
